1. Home
  2. MXL vs IMNM Comparison

MXL vs IMNM Comparison

Compare MXL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxLinear Inc.

MXL

MaxLinear Inc.

HOLD

Current Price

$93.87

Market Cap

3.0B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$22.00

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXL
IMNM
Founded
2003
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
2.6B
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
MXL
IMNM
Price
$93.87
$22.00
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
10
Target Price
$41.67
$32.80
AVG Volume (30 Days)
4.9M
900.7K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
46.08
51.40
EPS
N/A
N/A
Revenue
$478,596,000.00
$6,941,000.00
Revenue This Year
$22.10
N/A
Revenue Next Year
$10.70
$1,127.34
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.26
$7.96
52 Week High
$106.28
$27.65

Technical Indicators

Market Signals
Indicator
MXL
IMNM
Relative Strength Index (RSI) 64.07 49.13
Support Level $15.36 $19.28
Resistance Level $104.27 $23.25
Average True Range (ATR) 11.84 1.22
MACD -2.00 0.05
Stochastic Oscillator 52.17 56.39

Price Performance

Historical Comparison
MXL
IMNM

About MXL MaxLinear Inc.

MaxLinear Inc is a provider of radio frequency and mixed-signal integrated circuits for cable and satellite broadband communications, the connected home, and for data center, metro, and long-haul fiber networks. The company's radio frequency receiver products capture and process digital and analog broadband signals to be decoded for various applications. Its product options include both radio frequency receivers and radio frequency receiver systems-on-chips. The company's products enable the distribution and display of broadband video and data content in a wide range of electronic devices.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: